{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:39:29Z","timestamp":1790998769420,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T00:00:00Z","timestamp":1455062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jphs.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,2,15]],"date-time":"2016-02-15T19:20:33Z","timestamp":1455564033000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects"],"prefix":"10.1016","volume":"130","author":[{"given":"Atsuo","family":"Tahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Yokono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2016.02.003_bib1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2016.02.003_bib2","first-page":"255","article-title":"Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus","volume":"18","author":"Rossetti","year":"1995","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.jphs.2016.02.003_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc08-9016","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2016.02.003_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabet"},{"key":"10.1016\/j.jphs.2016.02.003_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jphs.2016.02.003_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"11","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jphs.2016.02.003_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in\u00a0vitro and in\u00a0vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.jphs.2016.02.003_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.112.191593","article-title":"Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice","volume":"341","author":"Suzuki","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib12","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2016.02.003_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1124\/jpet.113.203869","article-title":"Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats","volume":"345","author":"Kojima","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jphs.2016.02.003_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40265-014-0229-1","article-title":"Tofogliflozin: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jphs.2016.02.003_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12325-015-0200-x","article-title":"Pharmacokinetics, pharmacodynamics, and safety of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, single-blind, placebo-controlled trial","volume":"32","author":"Sasaki","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40262-014-0180-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin","volume":"53","author":"Kadokura","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jphs.2016.02.003_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In\u00a0vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans","volume":"38","author":"Obermeier","year":"2010","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.jphs.2016.02.003_bib19","first-page":"145","article-title":"Canagliflozin (INVOKANA\u00ae): a first-in-class anti-diabetic drug","volume":"3","author":"Sen","year":"2013","journal-title":"J\u00a0Drug Deliv Ther"},{"key":"10.1016\/j.jphs.2016.02.003_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jphs.2016.02.003_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jphs.2015.04.001","article-title":"In\u00a0vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: inhibition kinetics and binding studies","volume":"128","author":"Uchida","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2016.02.003_bib22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1463-1326.2009.01160.x","article-title":"Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature","volume":"12","author":"Nalysnyk","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jphs.2016.02.003_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1758-5996-6-54","article-title":"Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers","volume":"6","author":"Yamazaki","year":"2014","journal-title":"Diabetol Metab Syndr"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861316000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T03:03:22Z","timestamp":1536980602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861316000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1347861316000244"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2016.02.003","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}